There are 20200 possible amino-acid sequences for a 200-residue protein, of which the
natural evolutionary process has sampled only an infinitesimal subset. De novo protein …

While scientific advances have led to large-scale production and widespread distribution of
vaccines and antiviral drugs, viruses still remain a major cause of human diseases today …

We developed a de novo protein design strategy to swiftly engineer decoys for neutralizing
pathogens that exploit extracellular host proteins to infect the cell. Our pipeline allowed the …

De novo protein design holds promise for creating small stable proteins with shapes
customized to bind therapeutic targets. We describe a massively parallel approach for …

Proteins with desired functions and properties are important in fields like nanotechnology
and biomedicine. De novo protein design enables the production of previously unseen …

Influenza virus remains a threat because of its ability to evade vaccine-induced immune
responses due to antigenic drift. Here, we describe the isolation, evolution, and structure of a …

De novo protein design enhances our understanding of the principles that govern protein
folding and interactions, and has the potential to revolutionize biotechnology through the …

Influenza therapeutics with new targets and mechanisms of action are urgently needed to
combat potential pandemics, emerging viruses, and constantly mutating strains in …

INTRODUCTION Annual influenza epidemics and episodic pandemics continue to cause
widespread illness and mortality. Strategies to prevent and treat acute influenza infection …

Although vaccines confer protection against influenza A viruses, antiviral treatment becomes
the first line of defense during pandemics because there is insufficient time to produce …